Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Nature Communications|May 6, 2018
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasisSean P Pitroda, Nikolai N Khodarev, Lei Huang, et al.
Nature Communications|November 15, 2018
Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasisSean P Pitroda, Nikolai N Khodarev, Lei Huang, et al.
Annals of Surgery|March 13, 2013
Optimal management of gastric cancer: results from an international RAND/UCLA expert panelNatalie Coburn, Rajini Seevaratnam, Lawrence Paszat, et al.
Surgery|October 1, 2013
What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panelMatthew Dixon, Alyson Mahar, Lawrence Paszat, et al.
Cancer Discovery|November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic DiseaseDaniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.
Annals of Surgical Oncology|September 4, 2012
A RAND/UCLA appropriateness study of the management of familial gastric cancerMatthew Dixon, Rajini Seevaratnam, Debrah Wirtzfeld, et al.
Cancer Research|October 27, 2012
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancersRifat Hasina, Nathan Mollberg, Ichiro Kawada, et al.
Annals of Surgery|August 7, 2018
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled TrialJames Fleshman, Megan E Branda, Daniel J Sargent, et al.
JAMA Surgery|November 15, 2013
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panelSavtaj S Brar, Alyson L Mahar, Lucy K Helyer, et al.
JAMA Network Open|February 15, 2020
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical TrialDaniel V T Catenacci, Leah Chase, Samantha Lomnicki, et al.
Pageof 16